Toujeo is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years 1
Prescribing Infomation can be found through the links in the Product Cards at the bottom of the page
Toujeo Features
Toujeo® can give your patients sustained glycaemic control when administered once daily in the morning or evening*1
Toujeo® can give your patients flexibility around their injection time to fit in with their daily lives when needed*†1
The pen that was rated by 97.5% of adult patients as easy to use‡5
The highest unit capacity of any basal insulin pen on the market1-5
Toujeo® can give your patients sustained glycaemic control when administered once daily in the morning or evening*1
Toujeo® can give your patients flexibility around their injection time to fit in with their daily lives when needed*†1
The pen that was rated by 97.5% of adult patients as easy to use‡5
The highest unit capacity of any basal insulin pen on the market1-5
Switching from GLP-1RA to a basal insulin
Watch and download these resources to assist you in starting Toujeo Solostar in a patient currently prescribed a GLP-1RA for whom insulin might be an option.
Medical supervision with close metabolic monitoring is recommended during any switch of therapy or initiation of insulin, and in the initial weeks thereafter.
Start and Switch Guide
Download this summary guide on how to start or switch diabetes patients to Toujeo.
Once Daily GLP-1 to Toujeo
Anne Goodchild (DSN and Lead Trainer for PITStop) shares guidance and practical recommendations and tips of how she would transition a patient with T2DM moving from a daily GLP-1 to Toujeo SoloStar.
This includes DVLA guidance, navigating your way through NICE and other things to consider such as OAD and therapy injection sites.
Once Weekly GLP-1 to Toujeo
PITStop lead coach and DSN, Anne Goodchild, shares guidance and recommendations on how to transition patients with Type 2 diabetes from a weekly GLP-1 to Toujeo SoloStar.
Anne shares practical advice and DVLA guidelines, navigating NICE guidelines and other things to think about like OAD therapy and injection sites.
How to Order Toujeo?
Presentation |
PIP Code |
Toujeo NHS list price |
Toujeo® SoloSTAR® |
3981354 |
GB: £32.14 NI: £53.57 |
Toujeo® DoubleSTAR® |
4104782 |
GB: £64.27 NI: £64.27 |
Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day.
There are two channels through which you can order Toujeo.
Via AAH:
- Community Pharmacy - 0344 561 8899
- Dispensing Doctors - 0344 561 8899
- Hospitals - 0344 561 6699
Via Phoenix:
- 01928 750 500 / 01928 750 750
If you are having any issues in getting stock of Toujeo from the above wholesalers, in that instance please contact Sanofi Customer Service on 0800 854 430 for further support.
*1 Becker R, et al. Diabetes Care. 2015;38:637-643;2
*†1 Toujeo® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6938/smpc. [Accessed: October 2024]
- Toujeo® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6938/smpc. [Accessed October 2024].
- Lantus® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2376/smpc. [Accessed October 2024].
- Tresiba® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2944/smpc. [Accessed October 2024].
- Levemir ®Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5536/smpc.[Accessed October 2024].
- Singh R, et al. Eur Endocrinol. 2018;14;47–51
- Toujeo is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years 7
‡5 Pohlmeier H, et al. J Diabetes Sci Technol.2017:11;263-269
Expert Videos
Diabetes Products
Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.1
For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >
T1DM – Type 1 Diabetes
T2DM – Type 2 Diabetes
MAT-XU-2302426 (v12.0) Date of Preparation: October 2024